The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales.
McCarthy, Eoghan M
The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. [electronic resource] - Rheumatology (Oxford, England) 06 2017 - 1041-1043 p. digital
Publication Type: Letter; Research Support, Non-U.S. Gov't
1462-0332
10.1093/rheumatology/kex044 doi
Antibodies, Monoclonal, Humanized--therapeutic use
England
Humans
Immunosuppressive Agents--therapeutic use
Lupus Erythematosus, Systemic--drug therapy
Practice Guidelines as Topic
Rituximab--therapeutic use
Wales
The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. [electronic resource] - Rheumatology (Oxford, England) 06 2017 - 1041-1043 p. digital
Publication Type: Letter; Research Support, Non-U.S. Gov't
1462-0332
10.1093/rheumatology/kex044 doi
Antibodies, Monoclonal, Humanized--therapeutic use
England
Humans
Immunosuppressive Agents--therapeutic use
Lupus Erythematosus, Systemic--drug therapy
Practice Guidelines as Topic
Rituximab--therapeutic use
Wales